Oncology Institute, Inc. (TOI)

In November 2025, TOI reported strong Q3 results and raised full-year guidance, leading to a stock rally. In December 2025, an independent director intended to sell 96,000 shares. In March 2026, the company announced Q4 and full-year 2025 earnings, surpassing expectations and achieving its first profitable quarter, resulting in a positive stock reaction. In April 2026, Minh Merchant was appointed as Chief Legal Officer, and the company achieved $1.8 million in Medicare savings. In May 2026, TOI reported Q1 2026 earnings, surpassing expectations and leading to a stock price increase.

Demand seasonality for The Oncology Institute is influenced by patient deductible resets and annual drug price increases. The first quarter is typically the lowest period due to these factors, but the company anticipates seasonal improvement in the second quarter as deductibles are satisfied.

The Oncology Institute, Inc. (TOI), established in 2007 and based in Cerritos, California, operates in the Healthcare sector, focusing on value-based cancer care in community settings. TOI aims to reduce costs associated with oncological treatments and cancer patient management. The company operates through three segments: Patient Services, which includes a range of oncology care offered on both a fee-for-service and value-based model; Dispensary (Specialty Pharmacy), a significant growth driver providing medications for oncology treatment; and Clinical Trials & Other, involving clinical trial management and educational services.

The Oncology Institute operates over 100 clinics and affiliate locations across five states in the United States: California, Florida, Arizona, Nevada, and Oregon. As of December 31, 2023, the majority of TOI's capitation agreements and approximately 85% of its revenues were generated in California. The company is expanding its geographic coverage, including expansions in California and a growing presence in Florida.

The Oncology Institute maintains a positive brand reputation, particularly for its patient care model, and is recognized for its compassionate and community-based approach to cancer treatment. The value-based approach has reduced emergency department utilization and hospitalizations, saving more than $12,000 per patient. Employee reviews indicate a positive work environment. There have been no significantly negative events impacting the brand reputation in the past year.

The Oncology Institute, Inc. has a diverse ownership structure, with institutional ownership reaching approximately 67.5%. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. Founder ownership remains material at 11.5%. Insider sentiment has been negative, with insiders selling $58.1 million worth of stock over the last year, compared to $2.00 million purchased.